Risks
4 risks
Risk Intelligence
Reagent price increases from dollar strength
View Risks →
Thyrocare Technologies Ltd — Q4 FY26
Thyrocare delivered a strong Q4 FY26 with consolidated revenue of ₹224 crore (+20% YoY) and PAT of ₹48.7 crore (+128% YoY), driven by 21% growth in franchisee business and 23% in partnerships.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Thyrocare delivered a strong Q4 FY26 with consolidated revenue of ₹224 crore (+20% YoY) and PAT of ₹48.7 crore (+128% YoY), driven by 21% growth in franchisee business and 23% in partnerships. Test volumes surged 29% YoY due to aggressive biochemistry pricing, while gross margins expanded 113bps to 74.7% from vendor negotiations. Management guided for mid-to-high teens revenue growth in FY27, with 75% from volume and 25% from mix, and expects EBITDA margins to remain stable around 32-34% as operating leverage is reinvested into specialty expansion (genomics, allergy). Key risk: potential reagent price increases from dollar strength could pressure margins if not passed on.
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Test Volumes
210M
+23% YoY
Total tests processed in FY26; Q4 alone saw 29% YoY growth.
Franchise Count
10,800
+500 QoQ
Highest ever active franchises; management targets ~500 net adds per quarter.
Patients Served
19.2M
+15% YoY
FY26 total patients; reflects growing reach across India.
Complaints per Million Tests
3.06
-180bps YoY
Sustained six sigma quality; complaints reduced significantly.
Fast read
Guidance and risk preview
Management expects revenue growth of mid-to-high teens, driven primarily by volume (75%) and mix (25%), with no price increases planned.
Vendors have requested price increases due to dollar appreciation; if sustained, margins could be pressured unless passed on.
View Risks →